Skip to main content

Table 2 Patient background and molecular status of Cohort 1

From: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas

  All Group Aa Group Ba Group Ca Group Da p-valueb
Total 758 155 131 237 235  
Mean Age at diagnosis(year) 53.7 44.7 41.7 56.7 63.4 <0.0001
Sex M/F 426/332 90/65 75/56 134/103 127/108 0.87
Surgery n (%)
 Biopsy only 121 (16) 16 (10) 19 (15) 49 (21) 37 (16) 0.05
KPS n (%)
 100 160 (21) 66 (43) 51 (40) 26 (11) 17 (7) <0.0001
 90 268 (35) 63 (41) 58 (45) 83 (35) 64 (27)
 80 126 (17) 13 (8) 7 (5) 43 (18) 63 (27)
 70 94 (12) 6 (4) 8 (6) 38 (16) 42 (18)
  − 60 107 (14) 7 (5) 4 (3) 47 (20) 49 (21)
Adjuvant therapy n (%)
 CRT 559/748 (75) 83/150 (55) 70/131 (53) 201/235 (86) 205/232 (88) <0.0001
 Chemo only 58/748 (8) 32/150 (21) 5/131 (4) 7/235 (3) 14/232 (6)
 RT only 43/748 (6) 4/150 (3) 16/131 (12) 13/235 (6) 10/232 (4)
 None 88/748 (12) 31/150 (21) 40/131 (31) 14/235 (6) 3/232 (1)
Location n(%)
 Cerebrum (with frontal involvement) 370/756 (49) 119/154 (77) 82/131 (63) 86/237 (36) 83/234 (35) <0.0001
 Cerebrum (other) 348/756 (47) 34/154 (23) 48/131 (37) 122/237(53) 144/234 (63)
 Thalamus 25/756 (3) 1/154 (0.7) 0/131 (0) 18/237 (8) 6/234 (3)
 Infratentorium 13/756 (2) 0/154 (0) 1/131 (0.8) 11/237 (5) 1/234 (0.4)
Histology n (%)
 DA 63 (8) 12 (8) 26 (20) 19 (8) 6 (3) <0.0001
 AA 106 (14) 7 (5) 33 (25) 38 (16) 28 (12)
 GBM 337 (44) 9 (6) 7 (5) 136 (57) 185 (79)
 OA 67 (9) 30 (19) 28 (21) 6 (3) 3 (1)
 AOA 103 (14) 32 (21) 29 (22) 29 (12) 13 (6)
 OL 47 (6) 39 (25) 6 (5) 2 (1) 0 (0)
 AO 35 (5) 26 (17) 2 (2) 7 (3) 0 (0)
Molecular background n(%)
 Total 1p/19q loss 148/757 (20) 144/155 (93) 4/131 (3) 0/237 (0) 0/234 (0) <0.0001
MGMT methylation 386/755 (51) 143/155 (92) 88/129 (68) 72/236 (31) 83/235 (35) <0.0001
H3.3/H3.1 mutation 23/510 (5) 1/31 (3) 0/21 (0) 21/233 (9) 1/235 (0.4) 0.0001
BRAF V600E 12/506 (2) 0/31 (0) 0/21 (0) 9/233 (4) 3/221 (1) 0.21
CDKN2A
 Homozygous Del 116/505 (23) 4/89 (4) 7/86 (8) 37/163 (23) 68/167 (41) <0.0001
 Heterozygous Del 72/505 (14) 5/89 (6) 6/86 (7) 22/163 (13) 39/167 (23)  
  1. AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, AOA anaplastic oligoastrocytoma, Chemo Chemotherapy, CRT chemoradiotherapy, DA diffuse astrocytoma, Del Deletion, F Female, GBM glioblastoma, KPS Karnofsky Performance Status, M Male, N/A not available, OA oligoastrocytoma, OL oligodendroglioma, RT radiation therapy
  2. a Group A IDH mutated-TERT mutated, Group B IDH mutated-TERT wid-type, Group C IDH wild-type-TERT wild-type, Group D IDH mutated-TERT mutated
  3. bOne-way ANOVA was applied for age, and Pearson’s chi-square test was done for others in statistical analysis